Vasohibin-1 expression as a biomarker of aggressive nature in ductal adenocarcinoma of the prostate: a retrospective cohort study at two centres in Japan

ObjectivesVasohibin-1 (VASH1) is an endogenous angiogenesis regulator expressed in activated vascular endothelial cells. We previously reported that high VASH1 expression is a predictor of progression in acinar adenocarcinoma of the prostate. In this study, we evaluated the characteristics of ductal...

Full description

Saved in:
Bibliographic Details
Published in:BMJ open 2021-11, Vol.11 (11), p.e056439-e056439
Main Authors: Kobayashi, Hiroaki, Kosaka, Takeo, Mikami, Shuji, Kimura, Tokuhiro, Hongo, Hiroshi, Kosugi, Michio, Sato, Yasufumi, Oya, Mototsugu
Format: Article
Language:English
Subjects:
Adenocarcinoma - genetics
Angiogenesis
Antibodies
Antigens
Biomarkers
Cell Cycle Proteins - genetics
Cohort analysis
Endothelial Cells
Humans
Japan - epidemiology
Kinases
Male
Medical prognosis
Metastasis
Prostate
Prostate cancer
prostate disease
Prostatic Neoplasms - genetics
Retrospective Studies
surgical pathology
urological tumours
Urology
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ObjectivesVasohibin-1 (VASH1) is an endogenous angiogenesis regulator expressed in activated vascular endothelial cells. We previously reported that high VASH1 expression is a predictor of progression in acinar adenocarcinoma of the prostate. In this study, we evaluated the characteristics of ductal adenocarcinoma of the prostate by comparing the level of VASH1 expression between ductal and acinar adenocarcinoma specimens.Design and settingA retrospective cohort study at two centres in Japan.ParticipantsAmong the 1495 patients who underwent radical prostatectomy or transurethral resection for the past 15 years, a total of 14 patients diagnosed with ductal adenocarcinoma and 20 patients diagnosed with acinar adenocarcinoma with a Gleason score of 4+4 were included.InterventionsWe immunohistochemically examined the CD34 expression as the microvessel density (MVD) and activated endothelial cells as the VASH1 density (vessels per mm2).Primary and secondary outcome measuresThe primary outcome was the association of MVD and VASH1 density between ductal and acinar adenocarcinoma, and the secondary outcome was their oncological outcomes.ResultsNine patients (64.3%) with ductal adenocarcinoma were diagnosed at an advanced clinical stage, and five patients (35.7%) died from cancer during a median follow-up of 56.0 months. The VASH1 densities (mean±SD) in ductal and acinar adenocarcinoma were 45.1±18.5 vs 16.1±21.0 (p
ISSN:2044-6055
2044-6055
DOI:10.1136/bmjopen-2021-056439